Current and potential therapeutic uses of lanthanide radioisotopes

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 6, 2000, Pages 531-545

  Cutler, C S ^a   Smith, C J ^a   Ehrhardt, G J ^a   Tyler, T T ^a   Jurisson, S S ^b   Deutsch, E ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b Department of Chemistry ^*  (United States)

Author keywords

Lanthanides; Radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CYCLAM DERIVATIVE; DYSPROSIUM; EDETIC ACID; HOLMIUM; LANTHANIDE; LUTETIUM; METHYLPHOSPHONIC ACID; PENTETIC ACID; PROMETHIUM; RADIOISOTOPE; SAMARIUM 153; TECHNETIUM 99M; YTTERBIUM;

CANCER RADIOTHERAPY; DRUG CONJUGATION; HUMAN; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REVIEW;

EID: 0034518370     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.531     Document Type: Review

References (54)

1. Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate
2. Radiolabeling antibodies with holmium-166
3. 90Y radioimmunotherapy
4. Mechanism and energetics for complexation of 90Y with 1,4,7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a model for cancer radioimmunotherapy
5. In vivo use of radioiodinated somatostatin analogue: Dynamics, metabolism and binding to somatostatin receptor-positive tumors in man
6. 3] octreotide
7. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labeled with technetium-99m
8. In vitro and in vivo evaluation of copper-64-octreotide conjugates
9. PET pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO- and 86Y-DTPA-octreotide
10. 3]-octreotide: The Rotterdam experience with more than 1000 patients
11. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positro emission tomography imaging and targeted radiotherapy
12. Synthesis, radiolabelling, and evaluation of DTPA/octreotide conjugates for radiotherapy
13. 3-octreotide in tumor bearing rodents
14. Yttrium-90-DOTA-octreotide treatment of somatostatin receptor positive tumors
15. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats
16. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
17. Pharmacokinetic studies of 105Rh(III) complexes with macrocycles
18. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses
19. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies
20. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazayclododecanetetraacetate and related ligands: Kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid
21. Chelating ligands functionalized for facile attachment attachment to biomolecules. A convenient route to 4-isothiocyanatobenzyl derivatives of diethylenetriaminepentaacetic acid and ethylenediaminetetraacetic acid
22. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies
23. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium(III)
24. 111indium-DOTA chelates: A simple and efficient method
25. Stable bifunctional chelates of metals used in radiotherapy
26. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates
27. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates
28. Quantitative 5-minute radiolabeling of DOTA-HMAB conjugates with Y-90 for cancer radioimmunotherapy
29. Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates
30. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates
31. Synthesis of 2-(p-thiocyanatobenzyl)-1,4, 7-triazacyclononane-1,4,7-triacetic acid: Application of the 4-methoxy-2,3,6-trimethylbenzenesulfonamide protecting group in the synthesis of macrocyclic polyamines
32. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy
33. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
34. [DOTA, Tyr3] octreotate, labeled with Lu-177, is most promising for radionuclide therapy of somatostatin receptor-positive tumors
35. Skeletal localization of Sm-153 chelates: Potential therapeutic bone agents
36. Therapeutic radiopharmaceuticals
37. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma
38. Two phase I/II studies of 166Holmium-DOTMP in combination with melphalan with or without TBI as a preparative regimen for autologous stem cell transplant (PBSCT) for patients with multiple myeloma
39. Radiation synovectomy revisited
40. Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: Potential radiopharmaceuticals for radiation synovectomy
41. Samarium-153-particulate hydroxyapatite radiation synovectomy: Biodistribution data for chronic knee synovitis
42. Chromosomal analysis of peripheral lymphocytes of patients before and after radiation synovectomy with samarium-153 particulate hydroxyapatite
43. Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis
44. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma
45. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49
46. Quantitative imaging of yttrium-86 with PET: The occurrence and correction of anomalous apparent activity in high density regions
47. 3-octreotide: Preliminary report in cancer patients
48. 3-octreotate in CA20948 tumor-implanted Lewis rats
49. 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors
50. Ultrasound guided internal radiotherapy using yttrium-90 glass microspheres for liver malignancies
51. Yttrium-90-labeled human macroaggregated albumin for internal radiotherapy: Combined use with DTPA
52. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach